Peptide Offers: What's Running, and the Rules That Govern Them

What are peptide offers in an affiliate context?

Peptide offers are affiliate promotions for synthetic peptide compounds — BPC-157, TB-500, semaglutide, tirzepatide, retatrutide — pushed through two distinct funnel types. One sells "research use only" powder directly to consumers for self-injection. The other routes a lead through a telehealth quiz to a prescriber and a compounding pharmacy for a GLP-1 analog. Both convert on the same demand: fast weight loss and recovery claims that FDA-approved drugs address only through prescription channels.

What's actually running shifts month to month, since FDA warning letters take down individual sellers faster than new white-label shops can replace them. The peptide affiliate offers page tracks which verticals are live and which have gone quiet this year. Retatrutide has displaced semaglutide as the highest-converting angle in mid-2026, largely on the strength of Eli Lilly's Phase 3 trial data circulating in ad copy well ahead of any FDA approval.

The two funnel types carry different exposure and should not be treated as one category. A "research use only" peptide sale is, per FDA's own enforcement letters, treated as an unapproved new drug the moment the marketing implies human use — the RUO label does not change that finding. A GLP-1 telehealth funnel operates inside a narrower, shrinking carve-out for compounding pharmacies that FDA has been actively closing since early 2025.

How do peptides differ regulatorily from ordinary supplements?

Most peptides sold in this niche do not fit the legal definition of a dietary supplement at all. Under 21 U.S.C. 321(ff)(1), a supplement must contain a vitamin, mineral, herb, amino acid or similar dietary substance intended to supplement the diet — a closed list. A synthetic compound like BPC-157 has no food history and no natural home on that list, which is why it gets regulated as a would-be drug rather than a supplement ingredient.

Food-derived peptides sit on the other side of that line and stay lawful. Collagen peptides and whey protein hydrolysates qualify as protein or amino-acid dietary substances and were sold as foods long before any drug investigation touched them, so the statute's drug-preclusion clause does not reach them; this reading is consistent with the statutory text but has not been separately confirmed against a specific agency ruling, so treat it as the likely position rather than settled law.

BPC-157's removal from FDA's Category 2 compounding list in April 2026 reads like a loosening to most sellers running this vertical, but it is closer to the opposite. Category 2 substances at least sat under an interim enforcement-discretion posture; on FDA's May 2026 bulk substances list, Category 2 contains only six substances, and BPC-157 now appears in none of Categories 1, 2 or 3 — meaning it lost even that conditional footing without gaining any lawful compounding basis.

What claims can and cannot be made?

What you can claim is narrower than what the traffic wants to hear, and both FDA and FTC have been explicit about where the line sits. A supplement crosses into drug-claim territory under 21 CFR 101.93(g)(2) the moment it claims to substitute for a therapy, augment a drug's action, or ease a named drug's side effects — precisely the "for Ozempic users" positioning much of this category runs on. Naming a prescription drug in supplement copy is, by FDA's own reading, evidence of a drug claim rather than a neutral comparison.

FDA's own language on the disclaimer question is blunt. In a March 2026 warning letter to Gram Peptides, the agency found that mechanism-of-action and weight-loss copy on a "research use only" product page established the product was intended as a drug for human use, regardless of the disclaimer sitting beside it. FTC guidance reaches the same conclusion from the consumer-protection side: a contradictory disclaimer does not neutralize the claim it sits next to. A VSL might claim a peptide accelerates tendon repair or extends lifespan; that claim belongs to the seller's script, and a publisher repeating it without keeping the attribution in the same sentence inherits it as their own ad claim.

FTC's weight-loss guidance also lists specific claims its experts treat as categorically false, which is useful as a hard no-list for review before an offer goes live:

• Losing 2 or more pounds a week for a month or longer without dieting or exercise
• Substantial weight loss no matter what or how much the consumer eats
• Permanent weight loss that continues after the consumer stops using the product
• Blocking fat or calorie absorption to produce substantial weight loss
• Safely losing more than 3 pounds a week for more than 4 weeks
• Substantial weight loss for all users, stated as a universal outcome
• Substantial weight loss from a product worn on the body or rubbed into skin

How do platforms treat this category?

Platforms treat peptide offers as pharmaceutical advertising, not supplement advertising, and gate accordingly. Meta will not run ads for prescription drugs without its own authorization, and per Meta's Advertising Standards restricts eligibility to online pharmacies, telehealth providers and pharmaceutical manufacturers that hold active LegitScript certification, with delivery limited to adults 18 and older in the US, Canada and New Zealand only.

Google applies a comparable filter. US-targeted campaigns need LegitScript or NABP certification for pharmacies, LegitScript certification for telemedicine providers, and separate advertiser certification on top of that; Google's published reference list of restricted prescription drug terms names semaglutide, tirzepatide and liraglutide directly. A supplement marketed as a "natural Ozempic" does not clear this by avoiding the brand name — Google's unapproved-substances rule bans implying equivalence to a prescription drug regardless of how the claim is worded.

Because the gate is real, a meaningful share of this traffic runs through landers built to show a compliant page to an automated reviewer and the offer page to the actual click. Enforcement of that practice varies sharply by network, and the network rules on cloaking cover which platforms tolerate it, which suspend accounts for it, and which sit in between.

What does the funnel usually look like?

The RUO funnel is short and transactional: an ad or organic post leads to a research-chemical storefront, the buyer selects a peptide and a vial size, and checkout often bundles in bacteriostatic water for reconstitution. FDA has flagged that bundling specifically — selling the water alongside a peptide that requires it was treated in one enforcement letter as independent evidence that the seller intended the product for human injection, not laboratory use.

The GLP-1 telehealth funnel runs longer and looks more like a legitimate care pathway on the surface. A quiz collects weight, height and medical history, a prescriber reviews it asynchronously, and an approved patient gets routed to a compounding pharmacy for a monthly shipment. The legal footing behind that pathway has narrowed sharply since 2025, as shortage-based enforcement discretion lapsed state by state and drug by drug.

Execution quality on either funnel tends to matter as much as the offer itself, since ad accounts in this vertical get reviewed and shut down at a higher rate than most verticals. Buyers running this category at scale often diversify execution geography the way they diversify creative, and the practical constraints of doing that are covered in running tier-1 offers from Ukraine.

Is this a category a newcomer should enter?

Not without dedicated compliance review built into the launch plan, and for most newcomers the honest answer is not yet. The regulatory ground has moved fast in the wrong direction for anyone hoping to run this loose: enforcement-discretion windows have closed, a bulk-substances list got smaller rather than larger, and telehealth-specific warning letters have run into the dozens in 2026 alone.

State enforcement adds a second layer most affiliates underweight. Alabama's attorney general shut down a clinic and secured a settlement over "pharmaceutical-grade" peptide claims, and Connecticut's attorney general has pursued both a raw-powder distributor and clinics on corporate-practice-of-medicine grounds. Neither action required a federal case — a state AG with a consumer-protection statute was enough on its own.

The scale of the underlying safety signal is part of why oversight keeps tightening rather than easing. FDA states plainly that retatrutide and cagrilintide cannot be used in compounding under federal law, and the same source reports 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide as of May 31, 2026 — likely an undercount, since state-licensed pharmacies face no federal requirement to report.

Operators looking for lower enforcement heat sometimes shift budget across borders rather than out of the category, and the trade-offs across major English-language markets are mapped in US vs UK vs Australia. That is a defensible move. Entering peptides cold, on borrowed creative and no legal review, is not.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Nutra niche intelligence directory, Back and Sciatic Pain Offers: Market Map and Claim Boundaries, Hemorrhoid Offers: High Urgency, High Shame, Tight Rules, Lung and Respiratory Offers: Small Market, Steep Claim Ceiling, Inflammation Offers: The Umbrella Angle Everyone Borrows, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.